Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc
Bullboard Posts
User Avatar Image
(15)
•••
Post by retiredcopon Sep 11, 2018 7:34pm
120 Views
Post# 28601162

Recent Article ON AD

Recent Article ON AD The 'three horsemen' that could help cure Alzheimer's
BAN2401 is joining Adacanumab and Leukine as drugs that are showing great promise to either cure or slow the progression of Alzheimer's disease.
Author: Mark Koebrich
Published: 1:48 PM MDT September 10, 2018
Updated: 6:55 PM MDT September 10, 2018
Despite the fact that Alzheimer's research continues to be a graveyard for a large number of drugs formulated to cure it, researchers now generally agree that they are finally getting closer to a solution.
There are currently three drugs in trials that are showing great promise. You might call them the three horsemen that could end the apocalypse that is Alzheimer's.

https://www.9news.com/article/news/health/the-three-horsemen-that-could-help-cure-alzheimers/73-592699038

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities